Assignment

Vinge has advised Pandox in connection with a directed share issue

March 30, 2017

Vinge has advised Pandox Aktiebolag (publ) in connection with a directed share issue of 7,499,99 class B shares at a subscription price of SEK 135 per share. Through the share issue, Pandox will obtain approximately SEK 1,012 million. The subscription price was determined through an accelerated book-building process. The share issue is directed to selected Swedish and international institutional investors. The purpose of the share issue is to, in a timely and cost efficient manner, enable a capital raising to finance acquisitions and thereby increase the company’s financial flexibility and mandate for continued value creation.
 
Pandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. The company’s shares are admitted to trading on Nasdaq Stockholm.
 
Vinge’s team primarily consisted of Jesper Schönbeck, Erik Sjöman, Nils Fredrik Dehlin, Tora Hansjons and Michaela Cronemyr.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025